1996 MD- School of Medicine; University of Lille, France
1997 MPH- School of Public Health, Bordeaux University, France
2000 MSc Epidemiology – School of Public Health, Harvard University, Boston, MA
2002 Ph.D – School of Public Health, Bordeaux University, France

2017- Director of the Infectiology, Inflammation, Immunology and Microbiology Institute at Inserm
2014- Coordinator of the French Inserm Reacting consortium: REsearch and ACTion targeting emerging infectious diseases that coordinates research during emerging infectious diseases epidemics.
2012- Head of Infectious Disease Department, Bichat Claude-Bernard Hospital, Paris.
2011- Professor of Infectious Disease, Paris VII Medical School, Bichat Claude-Bernard Hospital, Paris.
2011- ATIP-Avenir Inserm team on decision analysis and cost-effectiveness in infectious disease, Paris VII Medical School, Paris
2006-2011- Professor of Infectious Disease, Lille Medical School, Tourcoing Hospital, Lille University Hospital.
1999-2002- Chef de Clinique des Universités, Assistant des Hôpitaux in Infectious Disease Department, Lille Medical School, Tourcoing Hospital, Lille University Hospital.
1998-1999- Research fellow, Clinical Economics Research Unit, Boston City Hospital, Boston, MA
1996-1998- Research fellow, National Institute of Health and Medical Research (INSERM), St Antoine, Medical School, Paris
1990-1996- Resident/fellow in internal medicine, gastroenterology and infectious diseases, Lille Medical School, France
1993-1994- Fellow, St Louis Hospital, Senegal / Institute Pasteur de Lille, France

1997 MPH- School of Public Health, Bordeaux University, France
2000 MSc Epidemiology – School of Public Health, Harvard University, Boston, MA
2002 Ph.D – School of Public Health, Bordeaux University, France

2023

Mercier N, Belhadi D, DeChanet A, Delmas C, Saillard J, Dumousseaux M, Le Mestre S, Fougerou-Leurent C, Ferrane A, Burdet C, Espérou H, Ader F, Hites M, Peiffer-Smadja N, Poissy J, Andrejak C, Paiva JA, Tacconelli E, Staub T, Greil R, Costagliola D, Mentre F, Yazdanpanah Y, Diallo A, DSWg
Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial.
Pharmacology Research & Perspectives 2023, 11, e01072.

Bouzid D, Le Hingrat Q, Salipante F, Ferré V, Chevallier T, Tubiana S, Christophe Lucet J, Choquet C, Yazdanpanah Y, François Timsit J, Descamps D, Houhou N, Visseaux B, Loubet P
Agreement of respiratory viruses' detection between nasopharyngeal swab and bronchoalveolar lavage in adults admitted for pneumonia: a retrospective study.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2023, S1198-743X(23)00042-3.

de Lamballerie X, Martin-Blondel G, Dupont A, Izopet J, Mentré F, Kamar N, Autran B, Paintaud G, Caillard S, le Bourgeois A, Richez C, Couzi L, Xhaard A, Marjanovic Z, Avouac J, Jacquet C, Anglicheau D, Cheminant M, Yazdanpanah Y, Guyen SN, Terrier B, Gottenberg JE, Besson C, Letrou S, Kali S, Angoulvant D, Sanchez VP, Tardivon C, Blancho G, Lévy V
Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation.
The Journal of Infection 2023, 86, 66-117.

Touret F, Martin-Blondel G, de Lamballerie X, Dupont A, Izopet J, Mentré F, Kamar N, Autran B, Paintaud G, Caillard S, Richez C, Couzi L, Xhaard A, Marjanovic Z, Avouac J, Jacquet C, Anglicheau D, Cheminant M, Yazdanpanah Y, N'Guyen S, Terrier B, Gottenberg JE, Besson C, Letrou S, Kali S, Angoulvant D, Barthélémy K, Priet S, Nurtop E, Sanchez VP, Tardivon C, Blancho G, Le Bourgeois A, Lévy V
Low to undetectable Omicron BQ.1.1 neutralization by patient's sera a month after initiation of AZD7442 600 mg.
The Journal of Infection 2023, 86, e126-e129.

Brault A, Tran-Kiem C, Couteaux C, Olié V, Paireau J, Yazdanpanah Y, Ghosn J, Martin-Blondel G, Bosetti P, Cauchemez S
Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna.
The Lancet Regional Health. Western Pacific 2023, 30, 100634.

Amstutz A, Speich B, Mentré F, Rueegg CS, Belhadi D, Assoumou L, Burdet C, Murthy S, Dodd LE, Wang Y, Tikkinen KAO, Ader F, Hites M, Bouscambert M, Trabaud MA, Fralick M, Lee TC, Pinto R, Barratt-Due A, Lund-Johansen F, Müller F, Nevalainen OPO, Cao B, Bonnett T, Griessbach A, Taji Heravi A, Schönenberger C, Janiaud P, Werlen L, Aghlmandi S, Schandelmaier S, Yazdanpanah Y, Costagliola D, Olsen IC, Briel M
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials.
The Lancet. Respiratory Medicine 2023, 11, 453-464.

Terzić V, Levoyer L, Figarella M, Bigagli E, Mercier N, De Gastines L, Gibowski S, Trøseid M, Demotes J, Olsen IC, Hites M, Ader F, Lopez JRA, Mentré F, Espérou H, Costagliola D, Røttingen JA, Poissy J, Rozé JC, Warris A, O'Leary J, Fernandes RM, Assoumou L, Hankard R, Turner MA, Yazdanpanah Y, Diallo A, ERsg, csg
Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia.
British Journal of Clinical Pharmacology 2023, 89, 1318-1328.

Bertin C, Beaumont AL, Merlant M, Mailhe M, Le Pluart D, Deconinck L, Thy M, Cortier M, Garé M, Dollat M, Rahi M, Joly V, Lariven S, Rioux C, Truong A, Deschamps L, Ferré VM, Charpentier C, Lescure FX, Bouscarat F, Descamps V, Yazdanpanah Y, Peiffer-Smadja N
Erythematous maculopapular rash in monkeypox virus infection: a retrospective case series of 30 patients.
Journal of the European Academy of Dermatology and Venereology: JEADV 2023

Trøseid M, Arribas JR, Assoumou L, Holten AR, Poissy J, Terzić V, Mazzaferri F, Baño JR, Eustace J, Hites M, Joannidis M, Paiva JA, Reuter J, Püntmann I, Patrick-Brown TDJH, Westerheim E, Nezvalova-Henriksen K, Beniguel L, Dahl TB, Bouscambert M, Halanova M, Péterfi Z, Tsiodras S, Rezek M, Briel M, Ünal S, Schlegel M, Ader F, Lacombe K, Amdal CD, Rodrigues S, Tonby K, Gaudet A, Heggelund L, Mootien J, Johannessen A, Møller JH, Pollan BD, Tveita AA, Kildal AB, Richard JC, Dalgard O, Simensen VC, Baldé A, de Gastines L, Del Álamo M, Aydin B, Lund-Johansen F, Trabaud MA, Diallo A, Halvorsen B, Røttingen JA, Tacconelli E, Yazdanpanah Y, Olsen IC, Costagliola D, ESsg
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.
Critical Care (London, England) 2023, 27, 9.

Kali S, Bourner J, Calmy A, Laouénan C, Merson L, Cervantes-Gonzalez M, Rojek A, Pesonel E, Guiraud L, Tardivon C, Descamps D, Diallo A, Gibowski S, Rosenthal E, Petrov-Sanchez V, Letrou S, Hoffmann I, Le Mestre S, Mentré F, Yazdanpanah Y, Olliaro P, Lescure FX
[MOSAIC: a European cohort study of human Mpox - the challenges of clinical research in outbreaks].
Virologie (Montrouge, France) 2023, 27, 23-26.

Kali S, Bourner J, Calmy A, Laouénan C, Merson L, Cervantes-Gonzalez M, Rojek A, Pesonel E, Guiraud L, Tardivon C, Descamps D, Diallo A, Gibowski S, Rosenthal E, Petrov-Sanchez V, Letrou S, Hoffmann I, Le Mestre S, Mentré F, Yazdanpanah Y, Olliaro P, Lescure FX
MOSAIC: a European cohort study of human Mpox - the challenges of clinical research in outbreaks.
Virologie (Montrouge, France) 2023, 27, 12-15.

2022

Castry M, Cousien A, Champenois K, Supervie V, Velter A, Ghosn J, Yazdanpanah Y, Paltiel AD, Deuffic-Burban S
Cost-effectiveness of hepatitis C virus test-and-treat and risk reduction strategies among men who have sex with men living with HIV in France.
Journal of the International AIDS Society 2022, 25, e26035.

ERig, Diallo A, Trøseid M, Simensen VC, Boston A, Demotes J, Olsen IC, Chung F, Paiva JA, Hites M, Ader F, Arribas JR, Baratt-Due A, Melien Ø, Tacconelli E, Staub T, Greil R, Tsiodras S, Briel M, Esperou H, Mentré F, Eustace J, Saillard J, Delmas C, LeMestre S, Dumousseaux M, Costagliola D, Røttingen JA, Yazdanpanah Y
Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2022, 28, 1-5.

Trøseid M, Diallo A, Hites M, Røttingen JA, Yazdanpanah Y
Accelerating clinical trial implementation in the context of the COVID-19 pandemic: author's response.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2022, 28, 743-744.

Mailhe M, Beaumont AL, Thy M, Le Pluart D, Perrineau S, Houhou-Fidouh N, Deconinck L, Bertin C, Ferré VM, Cortier M, De La Porte Des Vaux C, Phung BC, Mollo B, Cresta M, Bouscarat F, Choquet C, Descamps D, Ghosn J, Lescure FX, Yazdanpanah Y, Joly V, Peiffer-Smadja N
Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection: an observational cohort study.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2022, S1198-743X(22)00428-1.

Dumont M, Guilhou T, Gerin M, Frémont-Goudot G, Nivose PL, Koubbi A, Joly V, Bouadma L, Yazdanpanah Y, André MH, de La Porte des Vaux C
Myocarditis in monkeypox-infected patients: a case series.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2022, S1198-743X(22)00604-8.

Méchaï F, Bachelet D, Han L, Dubert M, Parisey M, Cordel H, Bourgarit A, Bertrac C, Chauveau S, Billard-Pomares T, Carbonnelle E, Bouchaud O, Yazdanpanah Y, Vignier N, Laouénan C
Tuberculosis treatment outcomes among precarious patients in France.
Infectious Diseases Now 2022, 52, 389-395.

Bachelard A, Sautereau A, Digumber M, Isernia V, Phung B, Lehur AC, Gac SL, Landman R, Yazdanpanah Y, Ghosn J
Risk Factors Associated with Severe/Critical COVID-19 in People Living with HIV-1.
International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2022, 122, 152-154.

De Broucker C, Plessier A, Ollivier-Hourmand I, Dharancy S, Bureau C, Cervoni JP, Sogni P, Goria O, Corcos O, Sartoris R, Ronot M, Vilgrain V, de Raucourt E, Zekrini K, Davy H, Durand F, Payancé A, Fidouh-Houhou N, Yazdanpanah Y, Valla D, Rautou PE
Multicenter study on recent portal venous system thrombosis associated with cytomegalovirus disease.
Journal of Hepatology 2022, 76, 115-122.

Ferré VM, Lebourgeois S, Menidjel R, Collin G, Chenane HR, Guindi MO, Yazdanpanah Y, Timsit JF, Charpentier C, Descamps D, Fidouh N, Visseaux B
Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine.
The Journal of Infection 2022, 84, 248-288.

Lebourgeois S, Menidjel R, Chenane HR, Ferré VM, Collin G, Damond F, Coppée R, Yazdanpanah Y, Timsit JF, Houhou-Fidouh N, Descamps D, Charpentier C, Visseaux B
Alpha (B.1.1.7) and Delta (B.1.617.2 - AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage.
The Journal of Infection 2022, 84, 418-467.

Alidjinou EK, Demaret J, Corroyer-Simovic B, Labreuche J, Goffard A, Trauet J, Lupau D, Miczek S, Vuotto F, Dendooven A, Huvent-Grelle D, Podvin J, Dreuil D, Faure K, Deplanque D, Bocket L, Duhamel A, Sobaszek A, Hober D, Hisbergues M, Puisieux F, Autran B, Yazdanpanah Y, Labalette M, Lefèvre G
Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years.
The Lancet Regional Health. Europe 2022, 17, 100385.

Cortier M, de La Porte C, Papot E, Goudjo A, Guenneau L, Riou F, Cervantes-Gonzalez M, Prioux M, Yazdanpanah Y, Galy A
Health status and healthcare trajectory of vulnerable asylum seekers hosted in a French Reception Center.
Travel Medicine and Infectious Disease 2022, 46, 102180.

Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Lê MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F, DSG
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
The Lancet. Infectious Diseases 2022, 22, 209-221.

Colosi E, Bassignana G, Contreras DA, Poirier C, Boëlle PY, Cauchemez S, Yazdanpanah Y, Lina B, Fontanet A, Barrat A, Colizza V
Screening and vaccination against COVID-19 to minimise school closure: a modelling study.
The Lancet. Infectious Diseases 2022, S1473-3099(22)00138-4.

Hentzien M, Autran B, Piroth L, Yazdanpanah Y, Calmy A
A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab.
The Lancet. Infectious Diseases 2022, S1473-3099(22)00495-9.

Landman R, de Truchis P, Assoumou L, Lambert S, Bellet J, Amat K, Lefebvre B, Allavena C, Katlama C, Yazdanpanah Y, Molina JM, Petrov-Sanchez V, Gibowski S, Alvarez JC, Leibowitch J, Capeau J, Fellahi S, Duracinsky M, Morand-Joubert L, Costagliola D, Alvarez JC, Girard PM, A1Qsg
A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial.
The lancet. HIV 2022, 9, e79-e90.

Peyneau M, Granger V, Wicky PH, Khelifi-Touhami D, Timsit JF, Lescure FX, Yazdanpanah Y, Tran-Dinh A, Montravers P, Monteiro RC, Chollet-Martin S, Hurtado-Nedelec M, de Chaisemartin L
Innate immune deficiencies are associated with severity and poor prognosis in patients with COVID-19.
Scientific Reports 2022, 12, 638.

Thy M, Peiffer-Smadja N, Mailhe M, Kramer L, Ferré VM, Houhou N, Tarhini H, Bertin C, Beaumont AL, Garé M, Le Pluart D, Perrineau S, Rahi M, Deconinck L, Phung B, Mollo B, Cortier M, Cresta M, De La Porte Des Vaux C, Joly V, Lariven S, Rioux C, Somarriba C, Lescure FX, Charpentier C, Yazdanpanah Y, Ghosn J
Breakthrough Infections after Postexposure Vaccination against Mpox.
The New England Journal of Medicine 2022, 387, 2477-2479.

Eimer J, Fréchet-Jachym M, Le Dû D, Caumes E, El-Helali N, Marigot-Outtandy D, Mechai F, Peytavin G, Pourcher V, Rioux C, Yazdanpanah Y, Robert J, Guglielmetti L, Lg
Increased linezolid plasma concentrations are associated with the development of severe toxicity in MDR-TB treatment.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2022, ciac485.

Chalali F, Merlant M, Truong A, Ghosn J, Phung BC, Mollo B, Perrineau S, Rahi M, Fidouh-Houhou N, Ferré VM, Brunet-Possenti F, Descamps V, Bouscarat F, Yazdanpanah Y, Deschamps L, Bertin C
Histological features associated with Human Monkeypox Virus Infection in 2022 outbreak in a non-endemic country.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2022, ciac856.

Lingas G, Néant N, Gaymard A, Belhadi D, Peytavin G, Hites M, Staub T, Greil R, Paiva JA, Poissy J, Peiffer-Smadja N, Costagliola D, Yazdanpanah Y, Wallet F, Gagneux-Brunon A, Mentré F, Ader F, Burdet C, Guedj J, Bouscambert-Duchamp M
Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.
The Journal of Antimicrobial Chemotherapy 2022, 77, 1404-1412.

De Castro N, Mechaï F, Bachelet D, Canestri A, Joly V, Vandenhende M, Boutoille D, Kerjouan M, Veziris N, Molina JM, Grall N, Tattevin P, Laouénan C, Yazdanpanah Y, FTSG
Treatment With a Three-Drug Regimen for Pulmonary Tuberculosis Based on Rapid Molecular Detection of Isoniazid Resistance: A Noninferiority Randomized Trial (FAST-TB).
Open Forum Infectious Diseases 2022, 9, ofac353.

Le Pluart D, Ruyer-Thompson M, Ferré VM, Mailhe M, Descamps D, Bouscarat F, Lescure FX, Lucet JC, Yazdanpanah Y, Ghosn J
A Healthcare-Associated Infection With Monkeypox Virus of a Healthcare Worker During the 2022 Outbreak.
Open Forum Infectious Diseases 2022, 9, ofac520.

Kherabi Y, de Castro N, Sellier PO, Hamet G, Brun A, Méchaï F, Joly V, Yazdanpanah Y, Molina JM
Efficacy and safety of efavirenz, raltegravir and dolutegravir in HIV-1/TB co-infection. A multicenter retrospective cohort study in France.
Journal of Acquired Immune Deficiency Syndromes (1999) 2022

Chotard E, Jacquier H, Bart G, Richette P, Rioux C, Joly V, Goossens J, Palazzo E, Forien M, Jelin G, Yazdanpanah Y, Dieudé P, Le Goff B, Ottaviani S
MRI Features Associated With the Detection of Microbial Pathogens by CT-Guided Biopsy in Septic Spondylodiscitis.
Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases 2022, 28, e189-e194.

Bosetti P, Tran Kiem C, Andronico A, Colizza V, Yazdanpanah Y, Fontanet A, Benamouzig D, Cauchemez S
Epidemiology and control of SARS-CoV-2 epidemics in partially vaccinated populations: a modeling study applied to France.
BMC medicine 2022, 20, 33.

Ravalihasy A, Kardaś-Słoma L, Yazdanpanah Y, Ridde V
Quantitative methods used to evaluate impact of health promotion interventions to prevent HIV infections: a methodological systematic review protocol.
Systematic Reviews 2022, 11, 87.

Durand C, Douriez E, Chappuis A, Poulain F, Yazdanpanah Y, Lariven S, Lescure FX, Peiffer-Smadja N
Contributions and challenges of community pharmacists during the COVID-19 pandemic: a qualitative study.
Journal of Pharmaceutical Policy and Practice 2022, 15, 43.

Kherabi Y, Fréchet-Jachym M, Rioux C, Yazdanpanah Y, Méchaï F, Pourcher V, Robert J, Guglielmetti L, MTMG
Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019.
Emerging Infectious Diseases 2022, 28, 1796-1804.

2021

Cousien A, Acquaviva E, Kernéis S, Yazdanpanah Y, Delorme R
Temporal Trends in Suicide Attempts Among Children in the Decade Before and During the COVID-19 Pandemic in Paris, France.
JAMA network open 2021, 4, e2128611.

Yazdanpanah Y, FCciasg
Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID-19 patients.
Journal of Medical Virology 2021, 93, 2149-2159.

Peiffer-Smadja N, Rozencwajg S, Kherabi Y, Yazdanpanah Y, Montravers P
COVID-19 vaccines: a race against time.
Anaesthesia, Critical Care & Pain Medicine 2021, 100848.

Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, Delmas C, Saillard J, Dechanet A, Mercier N, Dupont A, Alfaiate T, Lescure FX, Raffi F, Goehringer F, Kimmoun A, Jaureguiberry S, Reignier J, Nseir S, Danion F, Clere-Jehl R, Bouiller K, Navellou JC, Tolsma V, Cabié A, Dubost C, Courjon J, Leroy S, Mootien J, Gaci R, Mourvillier B, Faure E, Pourcher V, Gallien S, Launay O, Lacombe K, Lanoix JP, Makinson A, Martin-Blondel G, Bouadma L, Botelho-Nevers E, Gagneux-Brunon A, Epaulard O, Piroth L, Wallet F, Richard JC, Reuter J, Staub T, Lina B, Noret M, Andrejak C, Lê MP, Peytavin G, Hites M, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F, Dsg
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2021, 27, 1826-1837.

Husain M, Rachline A, Cousien A, Rolland S, Rouzaud C, Ferre VM, Gomez MV, Le Teurnier M, Wicky-Thisse M, Descamps D, Yazdanpanah Y, Charpentier C, Pasquet-Cadre A
Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (March-May 2020).
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2021, 27, 1520.e1-1520.e5.

Gourjault C, Tarhini H, Rahi M, Thy M, Le Pluart D, Rioux C, Parisey M, Ismael S, Al Rida Aidibi A, Paradis V, Ghosn J, Yazdanpanah Y, Lescure FX, Gervais A
Cholangitis in three critically ill patients after a severe CoVID-19 infection.
IDCases 2021, e01267.

Telford E, Ortega-Perez I, Mellon G, Lacarra B, Adjadj E, Madelaine C, D'Ortenzio E, Yazdanpanah Y
Chronicles of a pandemic: how France coordinated the scientific research response to COVID-19.
Infectious Diseases Now 2021, S2666-9919(21)00487-5.

Nyirenda T, Bockarie M, Machingaidze S, Nderu M, Singh M, Fakier N, Habarugira JM, Beattie P, Pandya L, Jajkowicz D, Yazdanpanah Y, Hankins C, Makanga M
Strengthening capacity for clinical research in sub-Saharan Africa: partnerships and networks.
International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2021, 110, 54-61.

Lévy Y, Wiedemann A, Hejblum BP, Durand M, Lefebvre C, Surénaud M, Lacabaratz C, Perreau M, Foucat E, Déchenaud M, Tisserand P, Blengio F, Hivert B, Gauthier M, Cervantes-Gonzalez M, Bachelet D, Laouénan C, Bouadma L, Timsit JF, Yazdanpanah Y, Pantaleo G, Hocini H, Thiébaut R, FCcsg
CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death.
iScience 2021, 24, 102711.

Tubiana S, Burdet C, Houhou N, Thy M, Manchon P, Blanquart F, Charpentier C, Guedj J, Alavoine L, Behillil S, Leclercq A, Lucet JC, Yazdanpanah Y, Attia M, Demeret C, Rose T, Bielicki JA, Bruijning-Verhagen P, Goossens H, Descamps D, van der Werf S, Lina B, Duval X, Csg, Pi, SI
High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort.
The Journal of Infection 2021, 82, 186-230.

Lefrancq N, Paireau J, Hozé N, Courtejoie N, Yazdanpanah Y, Bouadma L, Boëlle PY, Chereau F, Salje H, Cauchemez S
Evolution of outcomes for patients hospitalised during the first 9 months of the SARS-CoV-2 pandemic in France: A retrospective national surveillance data analysis.
The Lancet Regional Health. Europe 2021, 5, 100087.

Fournier M, Faille D, Dossier A, Mageau A, Nicaise Roland P, Ajzenberg N, Borie R, Bouadma L, Bunel V, Castier Y, Choquet C, Crestani B, Daugas E, Deconinck L, Descamps D, Descamps V, Dieudé P, Ducrocq G, Faucher N, Goulenok T, Guidoux C, Khalil A, Lavallée P, Lescure FX, Lortat-Jacob B, Mal H, Mutuon P, Pellenc Q, Steg PG, Taille C, Timsit JF, Yazdanpanah Y, Papo T, Sacré K
Arterial Thrombotic Events in Adult Inpatients With COVID-19.
Mayo Clinic Proceedings 2021, 96, 295-303.

Tarhini H, Husain M, Poey N, Lariven S, Lescure FX, Yazdanpanah Y, Gervais A
Jaundice in a patient treated with Anakinra in a context of Covid-19.
Infectious Diseases Now 2021, 51, 217-218.

Sallard E, Belhadi D, Lescure FX, Yazdanpanah Y, Peiffer-Smadja N
Clinical trial protocols of repurposed prophylaxis for COVID-19: A review.
Infectious Diseases Now 2021, 51, 7-13.

Bendjelloul G, Gerard S, Birgand G, Lenne F, Rioux C, Lescure X, Yazdanpanah Y, Lucet JC
Impact of admission to high-risk isolation room on patients' and healthcare workers' perceptions: A qualitative cross-assessment Approach.
Infectious Diseases Now 2021, 51, 247-252.

Trøseid M, Hites M, Barratt-Due A, Ader F, Yazdanpanah Y
Assessing the evidence on remdesivir.
The Lancet. Infectious Diseases 2021, 21, 1630-1631.

Molina JM, Yazdanpanah Y, Afani Saud A, Bettacchi C, Chahin Anania C, DeJesus E, Olsen Klopfer S, Grandhi A, Eves K, Robertson MN, Correll T, Hwang C, Hanna GJ, Sklar P
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
The lancet. HIV 2021, 8, e324-e333.

Flament H, Rouland M, Beaudoin L, Toubal A, Bertrand L, Lebourgeois S, Rousseau C, Soulard P, Gouda Z, Cagninacci L, Monteiro AC, Hurtado-Nedelec M, Luce S, Bailly K, Andrieu M, Saintpierre B, Letourneur F, Jouan Y, Si-Tahar M, Baranek T, Paget C, Boitard C, Vallet-Pichard A, Gautier JF, Ajzenberg N, Terrier B, Pène F, Ghosn J, Lescure X, Yazdanpanah Y, Visseaux B, Descamps D, Timsit JF, Monteiro RC, Lehuen A
Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity.
Nature Immunology 2021, 22, 322-335.

Néant N, Lingas G, Le Hingrat Q, Ghosn J, Engelmann I, Lepiller Q, Gaymard A, Ferré V, Hartard C, Plantier JC, Thibault V, Marlet J, Montes B, Bouiller K, Lescure FX, Timsit JF, Faure E, Poissy J, Chidiac C, Raffi F, Kimmoun A, Etienne M, Richard JC, Tattevin P, Garot D, Le Moing V, Bachelet D, Tardivon C, Duval X, Yazdanpanah Y, Mentré F, Laouénan C, Visseaux B, Guedj J, FCCIaFCSg
Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort.
Proceedings of the National Academy of Sciences of the United States of America 2021, 118,

Casalino E, Bouzid D, Antoniol S, Choquet C, Colosi L, Pereira L, Agbessi A, Kenway P, Yazdanpanah Y, Ghazali DA
Assessment of HIV-postexposure prophylaxis prescription quality after a training programme and assistance in decisions provided by a computer-based decision program: a cross-over study.
Acta Clinica Belgica 2021, 1-15.

Sax PE, Rockstroh JK, Luetkemeyer AF, Yazdanpanah Y, Ward D, Trottier B, Rieger A, Liu H, Acosta R, Collins SE, Brainard DM, Martin H, GU3I
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2021, 73, e485-e493.

Tarhini H, Recoing A, Bridier-Nahmias A, Rahi M, Lambert C, Martres P, Lucet JC, Rioux C, Bouzid D, Lebourgeois S, Descamps D, Yazdanpanah Y, Le Hingrat Q, Lescure FX, Visseaux B
Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection.
The Journal of Infectious Diseases 2021, 223, 1522-1527.

Lê MP, Peiffer-Smadja N, Guedj J, Neant N, Mentré F, Ader F, Yazdanpanah Y, Peytavin G, C21DFSC
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response.
The Journal of Antimicrobial Chemotherapy 2021, 76, 277-279.

Bachelard A, Isernia V, Vallois D, Le Gac S, Chalal L, Landman R, Damond F, Descamps D, Yazdanpanah Y, Peytavin G, Ghosn J
Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection.
The Journal of Antimicrobial Chemotherapy 2021, 76, 2484-2485.

Smith GHR, Henry WK, Podzamczer D, Masiá MDM, Bettacchi CJ, Arasteh K, Jaeger H, Khuong-Josses MA, Montes-Ramírez ML, Stellbrink HJ, Yazdanpanah Y, Richmond GJ, Sutton KC, Zhang F, McCoig CC, St Clair MH, Vandermeulen K, Van Solingen-Ristea R, Smith KY, Margolis DA, Spreen WR
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.
Open Forum Infectious Diseases 2021, 8, ofab439.

Lahens A, Mullaert J, Gressens S, Gault N, Flamant M, Deconinck L, Joly V, Yazdanpanah Y, Lescure FX, Vidal-Petiot E
Association between renin-angiotensin-aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment.
Journal of Hypertension 2021, 39, 367-375.

Papot E, Kalampalikis N, Doumergue M, Pilorgé F, Quatremère G, Yazdanpanah Y, Préau M, AGsg
Can we talk about price with patients when choosing antiretroviral therapy? A survey with people living with HIV and prescribers in France.
BMJ open 2021, 11, e046212.

Mora M, Rincon G, Bourrelly M, Maradan G, Freire Maresca A, Michard F, Rouveix E, Pannetier J, Leriche D, Alain T, Yazdanpanah Y, Michels D, Spire B
Living conditions, HIV and gender affirmation care pathways of transgender people living with HIV in France: a nationwide, comprehensive, cross-sectional, community-based research protocol (ANRS Trans&HIV).
BMJ open 2021, 11, e052691.

Isernia V, Phung B, Lepretre AM, Azadi B, Rincon G, Zelie J, Le Gac S, Deprez A, Michard F, Yazdanpanah Y, Ghosn J
Pre-exposure HIV prophylaxis (PrEP) among transgender women: 3 years of follow-up in a university hospital in Paris.
Sexually Transmitted Infections 2021, 97, 465-466.

Rahi M, Le Pluart D, Beaudet A, Ismaël S, Parisey M, Poey N, Tarhini H, Lescure FX, Yazdanpanah Y, Deconinck L
Sociodemographic characteristics and transmission risk factors in patients hospitalized for COVID-19 before and during the lockdown in France.
BMC infectious diseases 2021, 21, 812.

Badio M, Lhomme E, Kieh M, Beavogui AH, Kennedy SB, Doumbia S, Leigh B, Sow SO, Diallo A, Fusco D, Kirchoff M, Termote M, Vatrinet R, Wentworth D, Esperou H, Lane HC, Pierson J, Watson-Jones D, Roy C, D'Ortenzio E, Greenwood B, Chêne G, Richert L, Neaton JD, Yazdanpanah Y, Pst
Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries.
Trials 2021, 22, 86.

Bosetti P, Kiem CT, Yazdanpanah Y, Fontanet A, Lina B, Colizza V, Cauchemez S
Impact of mass testing during an epidemic rebound of SARS-CoV-2: a modelling study using the example of France.
Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin 2021, 26,

Tran Kiem C, Crépey P, Bosetti P, Levy Bruhl D, Yazdanpanah Y, Salje H, Boëlle PY, Cauchemez S
Lockdown as a last resort option in case of COVID-19 epidemic rebound: a modelling study.
Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin 2021, 26,

Castry M, Cousien A, Bellet J, Champenois K, Pialoux G, Yazdanpanah Y, Costagliola D, Grabar S, Deuffic-Burban S, FHDoH(CFC
Hepatitis C virus (HCV) incidence among men who have sex with men (MSM) living with HIV: results from the French Hospital Database on HIV (ANRS CO4-FHDH) cohort study, 2014 to 2017.
Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin 2021, 26,

Lebourgeois S, Chenane HR, Houhou-Fidouh N, Menidjel R, Ferré VM, Collin G, Benmalek N, Coppée R, Larrouy L, Yazdanpanah Y, Timsit JF, Charpentier C, Descamps D, Visseaux B
Earlier In Vitro Viral Production With SARS-CoV-2 Alpha Than With Beta, Gamma, B, or A.27 Variants.
Frontiers in Cellular and Infection Microbiology 2021, 11, 792202.

Peiffer-Smadja N, Bridier-Nahmias A, Ferré VM, Charpentier C, Garé M, Rioux C, Allemand A, Lavallée P, Ghosn J, Kramer L, Descamps D, Yazdanpanah Y, Visseaux B
Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2.
Viruses 2021, 13, 1642.

Casalino E, Bouzid D, Antoniol S, Pinto A, Choquet C, Pereira L, Pavlovsky T, Ing V, Yazdanpanah Y, Ghosn J, Ghazali DA
Characteristics of human immunodeficiency virus exposure and predictors of time until access to postexposure prophylaxis: a prospective observational study.
Emergencias: Revista De La Sociedad Espanola De Medicina De Emergencias 2021, 33, 35-41.

2020

Bouadma L, Lescure FX, Lucet JC, Yazdanpanah Y, Timsit JF
Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists.
Intensive Care Medicine 2020, 46, 579-582.

Pichon M, Joly V, Argy N, Houze S, Bretagne S, Alanio A, Wassef M, Verillaud B, Yazdanpanah Y
Aspergillus flavus malignant external otitis in a diabetic patient: case report and literature review.
Infection 2020, 48, 193-203.

Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N
Type 1 interferons as a potential treatment against COVID-19.
Antiviral Research 2020, 178, 104791.

Loubet P, Tubiana S, Claessens Y, Epelboin L, Ficko C, Le Bel J, Rammaert B, Garin N, Prendki V, Stirnemann J, Leport C, Yazdanpanah Y, Varon E, Duval X, Claessens Y, Duval X, Bouvard E, Carette M, Debray M, Mayaud C, Leport C, Houhou N, Tubiana S, Benjoar M, Blanc F, Brun A, Epelboin L, Ficko C, Khalil A, Lefloch H, Naccache J, Rammaert B, Abry A, Allo J, Andre S, Andreotti C, Baarir N, Bendahou M, Benlafia L, Bernard J, Berthoumieu A, Billemont M, Bokobza J, Brun A, Burggraff E, Canavaggio P, Carette M, Casalino E, Castro S, Choquet C, Clément H, Colosi L, Dabreteau A, Damelincourt S, Dautheville S, Debray M, Delay M, Delerme S, Depierre L, Djamouri F, Dumas F, Fadel M, Feydey A, Freund Y, Garcia L, Goulet H, Hausfater P, Ilic-Habensus E, Josse M, Kansao J, Kieffer Y, Lecomte F, Lemkarane K, Madonna P, Meyniard O, Mzabi L, Pariente D, Pernet J, Perruche F, Piquet J, Ranerison R, Ray P, Renai F, Rouff E, Saget D, Saïdi K, Sauvin G, Trabattoni E, Trimech N, Auger C, Pasquet B, Tamazirt S, Treluyer J, Tubach F, Wang J, Chassany O, Misse C
Community-acquired pneumonia in the emergency department: an algorithm to facilitate diagnosis and guide chest CT scan indication.
Clinical Microbiology and Infection 2020, 26, 382.e1-382.e7.

Peiffer-Smadja N, Lucet JC, Bendjelloul G, Bouadma L, Gerard S, Choquet C, Jacques S, Khalil A, Maisani P, Casalino E, Descamps D, Timsit JF, Yazdanpanah Y, Lescure FX
Challenges and issues about organising a hospital to respond to the COVID-19 outbreak: experience from a French reference centre.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2020

Fragkou PC, Belhadi D, Peiffer-Smadja N, Moschopoulos CD, Lescure FX, Janocha H, Karofylakis E, Yazdanpanah Y, Mentré F, Skevaki C, Laouénan C, Tsiodras S, ESGfRV
Review of trials currently testing treatment and prevention of COVID-19.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2020, 26, 988-998.

Hingrat QL, Visseaux B, Laouenan C, Tubiana S, Bouadma L, Yazdanpanah Y, Duval X, Burdet C, Ichou H, Damond F, Bertine M, Benmalek N, Choquet C, Timsit JF, Ghosn J, Charpentier C, Descamps D, Houhou-Fidouh N, FCcmcCCsg, motFCcsg(ao, motCCsgPi, SC, CCCC, Casa, VL, BC, P, S, G
Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2020, S1198-743X(20)30721-7.

Dubert M, Visseaux B, Isernia V, Bouadma L, Deconinck L, Patrier J, Wicky PH, Le Pluart D, Kramer L, Rioux C, Le Hingrat Q, Houhou-Fidouh N, Yazdanpanah Y, Ghosn J, Lescure FX
Case report study of the first five COVID-19 patients treated with remdesivir in France.
International Journal of Infectious Diseases 2020, 98, 290-293.

Isernia V, Julia Z, Le Gac S, Bachelard A, Landman R, Lariven S, Joly V, Deconinck L, Rioux C, Lescure X, Yazdanpanah Y, Ghosn J
SARS-COV2 infection in 30 HIV-infected patients followed-up in a French University Hospital.
International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2020, 101, 49-51.

San C, Lê MP, Matheron S, Mourvillier B, Caseris M, Timsit JF, Wolff M, Yazdanpanah Y, Descamps D, Peytavin G
Management of oral antiretroviral administration in patients with swallowing disorders or with an enteral feeding tube.
Medecine Et Maladies Infectieuses 2020, 50, 537-544.

Pizzorno A, Padey B, Julien T, Trouillet-Assant S, Traversier A, Errazuriz-Cerda E, Fouret J, Dubois J, Gaymard A, Lescure FX, Dulière V, Brun P, Constant S, Poissy J, Lina B, Yazdanpanah Y, Terrier O, Rosa-Calatrava M
Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia.
Cell Reports Medicine 2020, 1, 100059.

Gilbert M, Pullano G, Pinotti F, Valdano E, Poletto C, Boëlle PY, D'Ortenzio E, Yazdanpanah Y, Eholie SP, Altmann M, Gutierrez B, Kraemer MUG, Colizza V
Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study.
The Lancet 2020, 395, 871-877.

Jouvin-Marche E, Carrara G, Pulcini C, Andremont A, Danan C, Couderc-Obert C, Lienhardt C, Kieny MP, Yazdanpanah Y
French research strategy to tackle antimicrobial resistance.
The Lancet 2020, 395, 1239-1241.

Norton A, Mphahlele J, Yazdanpanah Y, Piot P, Bayona MT
Strengthening the global effort on COVID-19 research.
The Lancet 2020, S0140673620315981.

Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, Gaymard A, Bouscambert-Duchamp M, Donati F, Le Hingrat Q, Enouf V, Houhou-Fidouh N, Valette M, Mailles A, Lucet JC, Mentre F, Duval X, Descamps D, Malvy D, Timsit JF, Lina B, van-der-Werf S, Yazdanpanah Y
Clinical and virological data of the first cases of COVID-19 in Europe: a case series.
The Lancet. Infectious Diseases 2020, 20, 697-706.

Atlani-Duault L, Lina B, Malvy D, Yazdanpanah Y, Chauvin F, Delfraissy JF
COVID-19: France grapples with the pragmatics of isolation.
The Lancet. Public Health 2020, 5, e573-e574.

Couffignal C, Papot E, Etienne A, Legac S, Laouénan C, Beres D, Blum L, Khuong-Josses MA, Lepretre A, Papazian P, Yazdanpanah Y, Bouvet E
Treatment as prevention (TasP) and perceived sexual changes in behavior among HIV-positive persons: a French survey in infectious diseases departments in Paris.
AIDS care 2020, 32, 811-817.

Luong Nguyen LB, Freedberg KA, Wanjala S, Maman D, Szumilin E, Mendiharat P, Yazdanpanah Y
Comparative effectiveness of interventions to improve the HIV continuum of care and HIV Pre-Exposure Prophylaxis in Kenya: a model-based analysis.
The Journal of Infectious Diseases 2020

Charpentier C, Peytavin G, Raffi F, Burdet C, Landman R, Lê MP, Katlama C, Collin G, Benalycherif A, Cabie A, Mentré F, Yazdanpanah Y, Descamps D, Joly V
Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).
The Journal of Antimicrobial Chemotherapy 2020, 75, 1611-1617.

Boyd A, Miailhes P, Chas J, Valantin MA, Yazdanpanah Y, Rosenthal E, Chevaliez S, Piroth L, Rougier H, Peytavin G, Pialoux G, Girard PM, Lacombe K
Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM.
The Journal of Antimicrobial Chemotherapy 2020, 75, 1961-1968.

Lê MP, Peiffer-Smadja N, Guedj J, Néant N, Mentré F, Ader F, Yazdanpanah Y, Peytavin G
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
The Journal of Antimicrobial Chemotherapy 2020, 75, 2376-2380.

Argy N, Lariven S, Rideau A, Lemoine A, Bourgeois Moine A, Allal L, Choudat L, Ravel C, Michard F, Buffet P, Faye A, Houze S, Yazdanpanah Y
Congenital Leishmaniasis in a Newborn Infant Whose Mother was Coinfected With Leishmaniasis and HIV.
Journal of the Pediatric Infectious Diseases Society 2020, 9, 277-280.

Pichon M, Claire LP, Genet P, Caby F, Yazdanpanah Y, Menn AM
Adult-onset Still's disease in a patient with human immunodeficiency virus infection: pathophysiological link?.
Rheumatology (Oxford, England) 2020, 59, e99-e101.

Néant N, Lê MP, Bouazza N, Gattacceca F, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Solas C
Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients.
British Journal of Clinical Pharmacology 2020, 86, 2404-2413.

Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y
Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?.
Vox Sanguinis 2020, 115, 488-494.

Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C, Guivel-Benhassine F, Staropoli I, Chazal M, Dufloo J, Planas D, Buchrieser J, Rajah MM, Robinot R, Porrot F, Albert M, Chen KY, Crescenzo-Chaigne B, Donati F, Anna F, Souque P, Gransagne M, Bellalou J, Nowakowski M, Backovic M, Bouadma L, Le Fevre L, Le Hingrat Q, Descamps D, Pourbaix A, Laouénan C, Ghosn J, Yazdanpanah Y, Besombes C, Jolly N, Pellerin-Fernandes S, Cheny O, Ungeheuer MN, Mellon G, Morel P, Rolland S, Rey FA, Behillil S, Enouf V, Lemaitre A, Créach MA, Petres S, Escriou N, Charneau P, Fontanet A, Hoen B, Bruel T, Eloit M, Mouquet H, Schwartz O, van der Werf S
A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations.
Science Translational Medicine 2020, 12,

Visseaux B, Le Hingrat Q, Collin G, Bouzid D, Lebourgeois S, Le Pluart D, Deconinck L, Lescure FX, Lucet JC, Bouadma L, Timsit JF, Descamps D, Yazdanpanah Y, Casalino E, Houhou-Fidouh N, McAdam AJ
Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the First Rapid Multiplex PCR Commercial Assay for SARS-CoV-2 Detection.
Journal of Clinical Microbiology 2020, 58, e00630-20, /jcm/58/8/JCM.00630-20.atom.

Castry M, Cousien A, Supervie V, Velter A, Ghosn J, Paltiel AD, Yazdanpanah Y, Deuffic-Burban S
Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach.
Gut 2020

Dubert M, Visseaux B, Birgy A, Mordant P, Metivier AC, Dauriat G, Fidouh N, Yazdanpanah Y, Grall N, Castier Y, Mal H, Thabut G, Lescure FX
Late viral or bacterial respiratory infections in lung transplanted patients: impact on respiratory function.
BMC infectious diseases 2020, 20, 176.

Norton A, Sigfrid L, Aderoba A, Nasir N, Bannister PG, Collinson S, Lee J, Boily-Larouche G, Golding JP, Depoortere E, Carson G, Kerstiëns B, Yazdanpanah Y
Preparing for a pandemic: highlighting themes for research funding and practice—perspectives from the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R).
BMC Medicine 2020, 18, 273.

Kardaś-Słoma L, Yazdanpanah Y, Perozziello A, Zahar JR, Lescure FX, Cousien A, Lucet JC
Hand hygiene improvement or antibiotic restriction to control the household transmission of extended-spectrum β-lactamase-producing Escherichia coli: a mathematical modelling study.
Antimicrobial Resistance and Infection Control 2020, 9, 139.

Vallès X, Stenseth NC, Demeure C, Horby P, Mead PS, Cabanillas O, Ratsitorahina M, Rajerison M, Andrianaivoarimanana V, Ramasindrazana B, Pizarro-Cerda J, Scholz HC, Girod R, Hinnebusch BJ, Vigan-Womas I, Fontanet A, Wagner DM, Telfer S, Yazdanpanah Y, Tortosa P, Carrara G, Deuve J, Belmain SR, D’Ortenzio E, Baril L, Yang R
Human plague: An old scourge that needs new answers.
PLOS Neglected Tropical Diseases 2020, 14, e0008251.

Fournier AL, Parienti JJ, Champenois K, Feret P, Papot E, Yazdanpanah Y, Verdon R
Incidence and risk factors for medical care interruption in people living with HIV in a French provincial city.
PloS One 2020, 15, e0240417.

Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Lamers MM, Sikkema RS, de Bruin E, Chandler FD, Yazdanpanah Y, Le Hingrat Q, Descamps D, Houhou-Fidouh N, Reusken CBEM, Bosch BJ, Drosten C, Koopmans MPG, Haagmans BL
Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients.
Emerging Infectious Diseases 2020, 26,

2019

Lê MP, Valantin M, Assoumou L, Soulie C, Le Mestre S, Weiss L, Yazdanpanah Y, Molina J, Bouchaud O, Raffi F, Reynes J, Calvez V, Marcelin A, Costagliola D, Katlama C, Peytavin G, AEsg, Duvivier C, Goujard C, Jeantils V, Salmon D, Simon A, Colin de Verdière N, Morlat P, Poizot‐Martin I, Allavena C, Naqvi A, Bernard L, Chidiac C, Hamdoud K
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS ‐163 ETRAL Study.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2019, 39, 514-520.

Peiffer-Smadja N, Harent S, Messeca C, Lechapt-Zalcman E, Yazdanpanah Y, Joly V
A case of thoracic actinomycosis presenting as sudden paraplegia.
Revue Neurologique 2019, 175, 89-92.

Wohl DA, Yazdanpanah Y, Baumgarten A, Clarke A, Thompson MA, Brinson C, Hagins D, Ramgopal MN, Antinori A, Wei X, Acosta R, Collins SE, Brainard D, Martin H
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
The lancet. HIV 2019, 6, e355-e363.

Vieillard V, Combadière B, Tubiana R, Launay O, Pialoux G, Cotte L, Girard PM, Simon A, Dudoit Y, Reynes J, Rockstroh J, Garcia F, Gatell J, Devidas A, Yazdanpanah Y, Weiss L, Fätkenheuer G, Autran B, Joyeux D, Gharakhanian S, Debré P, Katlama C
HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial.
NPJ vaccines 2019, 4, 25.

Parisey M, Louni F, Bouvet E, Landman R, Charpentier C, Lariven S, Joly V, Villemant A, Mackoumbou-Nkouka C, Yazdanpanah Y, Burdet C
HIV Infection in North African Patients.
AIDS research and human retroviruses 2019, 35, 628-633.

Joly V, Burdet C, Landman R, Vigan M, Charpentier C, Katlama C, Cabié A, Benalycherif A, Peytavin G, Yeni P, Mentre F, Argoud AL, Amri I, Descamps D, Yazdanpanah Y, LSG
Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).
The Journal of Antimicrobial Chemotherapy 2019, 74, 739-745.

Perrier M, Castain L, Regad L, Todesco E, Landman R, Visseaux B, Yazdanpanah Y, Rodriguez C, Joly V, Calvez V, Marcelin AG, Descamps D, Charpentier C
HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.
The Journal of Antimicrobial Chemotherapy 2019, 74, 1679-1692.

Néant N, Solas C, Bouazza N, Lê MP, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Gattacceca F
Concentration–response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients.
Journal of Antimicrobial Chemotherapy 2019, 74, 1992-2002.

Castain L, Perrier M, Charpentier C, Palich R, Desire N, Wirden M, Descamps D, Sayon S, Landman R, Valantin MA, Joly V, Peytavin G, Yazdanpanah Y, Katlama C, Calvez V, Marcelin AG, Todesco E
New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.
The Journal of Antimicrobial Chemotherapy 2019, 74, 2019-2023.

Perozziello A, Lescure FX, Truel A, Routelous C, Vaillant L, Yazdanpanah Y, Lucet JC, Csg
Prescribers' experience and opinions on antimicrobial stewardship programmes in hospitals: a French nationwide survey.
The Journal of Antimicrobial Chemotherapy 2019, 74, 2451-2458.

Katlama C, Assoumou L, Valantin MA, Soulié C, Martinez E, Béniguel L, Bouchaud O, Raffi F, Molina JM, Fellahi S, Peytavin G, Marcelin AG, Kolta S, Capeau J, Gibowski S, Cardon F, Reynes J, Costagliola D, tmotA1Es, Bernard L, Bottero J, Bouchaud O, Chidiac C, Duvivier C, Goujard C, delMarGutiérrez M, Martinez E, Molina JM, Morlat P, Naqvi A, Podzamczer D, Poizot-Martin I, Raffi F, Reynes J, Salmon-Céron D, Simon A, Valantin MA, Weiss L, Yazdanpanah Y
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
Journal of Antimicrobial Chemotherapy 2019, 74, 2742-2751.

Rockstroh JK, Yazdanpanah Y
HepCare Europe: a new user-friendly hepatitis C care service model. What have we learned? What are the remaining challenges?.
Journal of Antimicrobial Chemotherapy 2019, 74, v2-v4.

Bertin C, Abbas R, Andrieu V, Michard F, Rioux C, Descamps V, Yazdanpanah Y, Bouscarat F
Illicit massive silicone injections always induce chronic and definitive silicone blood diffusion with dermatologic complications.
Medicine 2019, 98, e14143.

Pommier JD, Laouénan C, Michard F, Papot E, Urios P, Boutten A, Peytavin G, Ghander C, Lariven S, Castanedo G, Moho D, Landman R, Phung B, Perez E, Julia Z, Descamps D, Roland-Nicaise P, Le Gac S, Yazdanpanah Y, Guibourdenche J, Yeni P
Metabolic syndrome and endocrine status in HIV-infected transwomen.
AIDS (London, England) 2019, 33, 855-865.

Januel E, Godin O, Moulignier A, Lescure FX, Savatovsky J, Lamirel C, Valin N, Tubiana R, Canestri A, Roux P, Sadik JC, Salomon L, Katlama C, Yazdanpanah Y, Pialoux G, Girard PM, Costagliola D, Assoumou L, MBRAK(SG
Brief Report: Impact of ART Classes on the Increasing Risk of Cerebral Small-Vessel Disease in Middle-Aged, Well-Controlled, cART-Treated, HIV-Infected Individuals.
Journal of Acquired Immune Deficiency Syndromes (1999) 2019, 81, 547-551.

Lê MP, Chaix M, Raffi F, Chevret S, Gallien S, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina J, Peytavin G, tADsg
Once‐daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS ‐165 DARULIGHT study.
British Journal of Clinical Pharmacology 2019, 85, 277-280.

Gobat N, Amuasi J, Yazdanpanah Y, Sigfid L, Davies H, Byrne JP, Carson G, Butler C, Nichol A, Goossens H
Advancing preparedness for clinical research during infectious disease epidemics.
ERJ open research 2019

tPst, Lhomme E, Modet C, Augier A, Faye S, Dabakuyo-Yonli TS, Levy-Marchal C, D’Ortenzio E, Yazdanpanah Y, Chêne G, Beavogui AH, Richert L
Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic context.
Trials 2019, 20,

Fournier AL, Yazdanpanah Y, Verdon R, Lariven S, Mackoumbou-Nkouka C, Phung BC, Papot E, Parienti JJ, Landman R, Champenois K, Yotebieng M
Incidence of and risk factors for medical care interruption in people living with HIV in recent years.
PLOS ONE 2019, 14, e0213526.

Cossais S, Schwarzinger M, Pol S, Fontaine H, Larrey D, Pageaux GP, Canva V, Mathurin P, Yazdanpanah Y, Deuffic-Burban S, Fischer F
Quality of life in patients with chronic hepatitis C infection: Severe comorbidities and disease perception matter more than liver-disease stage.
PLOS ONE 2019, 14, e0215596.

Raben D, Sullivan AK, Mocroft A, Kutsyna G, Hadžiosmanović V, Vassilenko A, Chkhartisvili N, Mitsura V, Pedersen C, Anderson J, Begovac J, Bak Dragsted U, Bertisch B, Grzeszczuk A, Minton J, Necsoi VC, Kitchen M, Ajana F, Sokhan A, Comi L, Farazmand P, Pesut D, De Wit S, Gatell JM, Gazzard B, d’Arminio Monforte A, Rockstroh JK, Yazdanpanah Y, Champenois K, Jakobsen ML, Lundgren JD, obotHSG, Sagar M
Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study – 2012 – 2015.
PLOS ONE 2019, 14, e0220108.

Jannic A, Mammeri H, Larcher L, Descamps V, Tosini W, Phung B, Yazdanpanah Y, Bouscarat F
Orogenital Transmission of Neisseria meningitidis Causing Acute Urethritis in Men Who Have Sex with Men.
Emerging Infectious Diseases 2019, 25, 175-176.

Perrineau S, Lachâtre M, Lê MP, Rioux C, Loubet P, Fréchet-Jachym M, Gonzales MC, Grall N, Bouvet E, Veziris N, Yazdanpanah Y, Peytavin G
Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis.
The International Journal of Tuberculosis and Lung Disease 2019, 23, 99-104.

2018

Néant N, Gattacceca F, Lê MP, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Solas C
Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine.
European Journal of Clinical Pharmacology 2018, 74, 473-481.

Loubet P, Burdet C, Vindrios W, Grall N, Wolff M, Yazdanpanah Y, Andremont A, Duval X, Lescure FX
Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review.
Clin Microbiol Infect 2018, 24, 125-132.

Perozziello A, Routelous C, Charani E, Truel A, Birgand G, Yazdanpanah Y, Lescure FX, Lucet JC, CSG
Experiences and perspectives of implementing antimicrobial stewardship in five French hospitals: a qualitative study.
International Journal of Antimicrobial Agents 2018, 51, 829-835.

Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, Cossais S, Roudot-Thoraval F, Canva V, Mathurin P, Dhumeaux D, Yazdanpanah Y
Assessing the cost-effectiveness of hepatitis C screening strategies in France.
Journal of Hepatology 2018, 69, 785-792.

D'Ortenzio E, Lemaître N, Brouat C, Loubet P, Sebbane F, Rajerison M, Baril L, Yazdanpanah Y
Plague: Bridging gaps towards better disease control.
Medecine Et Maladies Infectieuses 2018, 48, 307-317.

Bleibtreu A, Grall N, Laissy JP, Rioux C, Strukov A, Lariven S, Yeni P, Yazdanpanah Y, Joly V
Contribution of brain imaging to the diagnosis of intracranial tuberculoma and other brain lesions in patients presenting with miliary tuberculosis.
Medecine Et Maladies Infectieuses 2018, 48, 533-539.

N'Diaye DS, Launay O, Picone O, Tsatsaris V, Azria E, Rozenberg F, Schwarzinger M, Yazdanpanah Y
Cost-effectiveness of vaccination against cytomegalovirus (CMV) in adolescent girls to prevent infections in pregnant women living in France.
Vaccine 2018, 36, 1285-1296.

Moulignier A, Savatovsky J, Assoumou L, Lescure FX, Lamirel C, Godin O, Valin N, Tubiana R, Canestri A, Roux P, Sadik JC, Salomon L, Abrivard M, Katlama C, Yazdanpanah Y, Pialoux G, Girard PM, Costagliola D, MBRaK(SG
Silent Cerebral Small-Vessel Disease Is Twice as Prevalent in Middle-Aged Individuals With Well-Controlled, Combination Antiretroviral Therapy-Treated Human Immunodeficiency Virus (HIV) Than in HIV-Uninfected Individuals.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2018, 66, 1762-1769.

Argy N, Le Gal S, Coppée R, Song Z, Vindrios W, Massias L, Kao WC, Hunte C, Yazdanpanah Y, Lucet JC, Houzé S, Clain J, Nevez G
Pneumocystis Cytochrome b Mutants Associated With Atovaquone Prophylaxis Failure as the Cause of Pneumocystis Infection Outbreak Among Heart Transplant Recipients.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2018, 67, 913-919.

Luong Nguyen LB, Yazdanpanah Y, Maman D, Wanjala S, Vandenbulcke A, Price J, Parker RA, Hennequin W, Mendiharat P, Freedberg KA
Voluntary Community Human Immunodeficiency Virus Testing, Linkage, and Retention in Care Interventions in Kenya: Modeling the Clinical Impact and Cost-effectiveness.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2018, 67, 719-726.

Perrier M, Visseaux B, Landman R, Joly V, Todesco E, Yazdanpanah Y, Calvez V, Marcelin AG, Descamps D, Charpentier C
No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
The Journal of Antimicrobial Chemotherapy 2018, 73, 173-176.

Le Meur L, Tantet C, Lê MP, Desselas E, Bonnal C, Lillo-Le-Louet A, Sonneville R, Massias L, Giraud J, Descamps D, Yazdanpanah Y, Lariven S, Peytavin G
Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis.
The Journal of Antimicrobial Chemotherapy 2018, 73, 1108-1110.

Charpentier C, Peytavin G, Lê MP, Joly V, Cabras O, Perrier M, Le Gac S, Phung B, Yazdanpanah Y, Descamps D, Landman R
High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort.
The Journal of Antimicrobial Chemotherapy 2018, 73, 1665-1671.

Lê MP, Chaix ML, Chevret S, Bertrand J, Raffi F, Gallien S, El Abbassi EMB, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G, A1DSG
Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
The Journal of Antimicrobial Chemotherapy 2018, 73, 2120-2128.

Mabileau G, Scutelniciuc O, Tsereteli M, Konorazov I, Yelizaryeva A, Popovici S, Saifuddin K, Losina E, Manova M, Saldanha V, Malkin JE, Yazdanpanah Y
Intervention Packages to Reduce the Impact of HIV and HCV Infections Among People Who Inject Drugs in Eastern Europe and Central Asia: A Modeling and Cost-effectiveness Study.
Open Forum Infectious Diseases 2018, 5, ofy040.

de Léotoing L, Yazdanpanah Y, Finkielsztejn L, Chaize G, Vainchtock A, Nachbaur G, Aubin C, Bonnet F
Costs associated with hospitalization in HIV-positive patients in France.
AIDS (London, England) 2018, 32, 2059-2066.

Champenois K, Seng R, Persoz A, Essat A, Gaud C, Laureillard D, Robineau O, Duvivier C, Yazdanpanah Y, Goujard C, Meyer L, APcsg
Calendar trends in sexual behaviours in a cohort of HIV-infected MSM at the era of treatment as prevention of HIV infection.
AIDS (London, England) 2018, 32, 1871-1879.

Cuzin L, Yazdanpanah Y, Huleux T, Cotte L, Pugliese P, Allavena C, Reynes J, Poizot-Martin I, Bani-Sadr F, Delpierre C, DSG
No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in France.
HIV medicine 2018, 19, 238-242.

Rosenthal E, Fougerou-Leurent C, Renault A, Carrieri MP, Marcellin F, Garraffo R, Teicher E, Aumaitre H, Lacombe K, Bailly F, Billaud E, Chevaliez S, Dominguez S, Valantin MA, Reynes J, Naqvi A, Cotte L, Metivier S, Leroy V, Dupon M, Allegre T, De Truchis P, Jeantils V, Chas J, Salmon-Ceron D, Morlat P, Neau D, Perré P, Piroth L, Pol S, Bourlière M, Pageaux GP, Alric L, Zucman D, Girard PM, Poizot-Martin I, Yazdanpanah Y, Raffi F, Pabic EL, Tual C, Pailhé A, Amri I, Bellissant E, Molina JM, AHSSG
Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
HIV medicine 2018, 19, 227-237.

Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, Colombo M, Cortez-Pinto H, Craxi A, Goldberg D, Gore C, Kautz A, Lazarus JV, Mendão L, Peck-Radosavljevic M, Razavi H, Schatz E, Tözün N, van Damme P, Wedemeyer H, Yazdanpanah Y, Zuure F, Manns MP
Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
Journal of Viral Hepatitis 2018, 25 Suppl 1, 6-17.

Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Mabileau G, Dhersin JS, Yazdanpanah Y
Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Journal of Viral Hepatitis 2018, 25, 1197-1207.

2017

Bleibtreu A, Arias P, Vallois D, Debit A, Lermuzeaux M, Rioux C, Cabras O, Lucet JC, Choquet C, Timsit JF, Yazdanpanah Y, Lescure FX
Delayed management of Staphyloccocus aureus infective endocarditis in a Middle East respiratory syndrome coronavirus possible case hospitalized in 2015 in Paris, France.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2017, 23, 416-417.

Loubet P, Voiriot G, Houhou-Fidouh N, Neuville M, Bouadma L, Lescure FX, Descamps D, Timsit JF, Yazdanpanah Y, Visseaux B
Impact of respiratory viruses in hospital-acquired pneumonia in the intensive care unit: A single-center retrospective study.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2017, 91, 52-57.

Deuffic-Burban S, Boursier J, Leroy V, Yazdanpanah Y, Castera L, Mathurin P
Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?.
Journal of Hepatology 2017, 66, 304-312.

Schwarzinger M, Baillot S, Yazdanpanah Y, Rehm J, Mallet V
Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008-2013: A nationwide retrospective cohort study.
Journal of Hepatology 2017, 67, 454-461.

Peiffer-Smadja N, Ouedraogo R, D'Ortenzio E, Cissé PN, Zeggani Z, Beavogui AH, Faye SL, Le Marcis F, Yazdanpanah Y, Nguyen VK
Vaccination and blood sampling acceptability during Ramadan fasting month: A cross-sectional study in Conakry, Guinea.
Vaccine 2017, 35, 2569-2574.

Post FA, Yazdanpanah Y, Schembri G, Lazzarin A, Reynes J, Maggiolo F, Yan M, Abram ME, Tran-Muchowski C, Cheng A, Rhee MS
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial.
HIV clinical trials 2017, 18, 135-140.

Pichon M, Mikail N, Ben Ali K, Rouzet F, Burdet C, Yazdanpanah Y, Joly V, Lepage L, Sarda-Mantel L
18FDG-PET/CT: a useful tool for the management of patients in infectious diseases.
Infect Dis (Lond) 2017, 49, 155-157.

Senard O, Burdet C, Visseaux B, Charpentier C, Le Gac S, Julia Z, Lariven S, Descamps D, Yazdanpanah Y, Yeni P, Joly V
Epidemiological Profile of Newly Diagnosed HIV-Infected Patients in Northern Paris: A Retrospective Study.
AIDS Res Hum Retroviruses 2017, 33, 11-16.

Vindrios W, Argy N, Le Gal S, Lescure FX, Massias L, Le MP, Wolff M, Yazdanpanah Y, Nevez G, Houze S, Dorent R, Lucet JC
Outbreak of Pneumocystis jirovecii Infection Among Heart Transplant Recipients: Molecular Investigation and Management of an Interhuman Transmission.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2017, 65, 1120-1126.

Madelain V, Le MP, Champenois K, Charpentier C, Landman R, Joly V, Yeni P, Descamps D, Yazdanpanah Y, Peytavin G
Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.
The Journal of Antimicrobial Chemotherapy 2017, 72, 1137-1146.

Perrier M, Charpentier C, Peytavin G, Lê M, Blondel L, Visseaux B, Joly V, Pinto A, Matheron S, Yazdanpanah Y, Descamps D, Landman R
Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
The Journal of Antimicrobial Chemotherapy 2017, 72, 1745-1751.

Perrier M, Bertine M, Le Hingrat Q, Joly V, Visseaux B, Collin G, Landman R, Yazdanpanah Y, Descamps D, Charpentier C
Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients.
The Journal of Antimicrobial Chemotherapy 2017, 72, 2954-2955.

Squires K, Bekker LG, Katlama C, Yazdanpanah Y, Zhou Y, Rodgers AJ, DiNubile MJ, Sklar PA, Leavitt RY, Teppler H
Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies.
Open Forum Infectious Diseases 2017, 4, ofw047.

Ragonnet R, Deuffic-Burban S, Boesecke C, Guiguet M, Lacombe K, Guedj J, Rockstroh JK, Yazdanpanah Y
Estimating the Time to Diagnosis and the Chance of Spontaneous Clearance During Acute Hepatitis C in Human Immunodeficiency Virus-Infected Individuals.
Open Forum Infectious Diseases 2017, 4, ofw235.

Papot E, Landman R, Louni F, Charpentier C, Peytavin G, Certain A, Fradet C, Castro DR, Preau M, Goujard C, Yeni P, Yazdanpanah Y, AGSG
Budget impact of antiretroviral therapy in a French clinic cohort.
AIDS (London, England) 2017, 31, 1271-1279.

Seng R, Ghislain M, Girard PM, Cotte L, Meybeck A, Raffi F, Abgrall S, Yazdanpanah Y, Goujard C, Dray-Spira R, Meyer L
Sub-Saharan African migrants have slower initial CD4+ cell recovery after combined antiretroviral treatment initiation than French natives.
AIDS (London, England) 2017, 31, 1323-1332.

Todesco E, Charpentier C, Bertine M, Wirden M, Storto A, Desire N, Grude M, Nguyen T, Sayon S, Yazdanpanah Y, Katlama C, Descamps D, Calvez V, Marcelin AG
Disparities in HIV-1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations.
HIV medicine 2017, 18, 696-700.

Kardaś-Słoma L, Lucet JC, Perozziello A, Pelat C, Birgand G, Ruppé E, Boëlle PY, Andremont A, Yazdanpanah Y
Universal or targeted approach to prevent the transmission of extended-spectrum beta-lactamase-producing Enterobacteriaceae in intensive care units: a cost-effectiveness analysis.
BMJ open 2017, 7, e017402.

Sugarman J, Revill P, Zoulim F, Yazdanpanah Y, Janssen HLA, Lim SG, Lewin SR
Ethics and hepatitis B cure research.
Gut 2017, 66, 389-392.

Veziris N, Bernard C, Guglielmetti L, Le Du D, Marigot-Outtandy D, Jaspard M, Caumes E, Lerat I, Rioux C, Yazdanpanah Y, Tiotiu A, Lemaitre N, Brossier F, Jarlier V, Robert J, Sougakoff W, Aubry A, CMatTCotCM, CMaTCotCM
Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors.
The European Respiratory Journal 2017, 49,

Guglielmetti L, Jaspard M, Le Dû D, Lachâtre M, Marigot-Outtandy D, Bernard C, Veziris N, Robert J, Yazdanpanah Y, Caumes E, Fréchet-Jachym M, FMTMG
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
The European Respiratory Journal 2017, 49,

Cousien A, Leclerc P, Morissette C, Bruneau J, Roy É, Tran VC, Yazdanpanah Y, Cox J
The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study.
BMC infectious diseases 2017, 17, 162.

Visseaux B, Burdet C, Voiriot G, Lescure FX, Chougar T, Brugiere O, Crestani B, Casalino E, Charpentier C, Descamps D, Timsit JF, Yazdanpanah Y, Houhou-Fidouh N
Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016.
PLoS One 2017, 12, e0180888.

Sullivan AK, Sperle I, Raben D, Amato-Gauci AJ, Lundgren JD, Yazdanpanah Y, Jakobsen SF, Tavoschi L
HIV testing in Europe: Evaluating the impact, added value, relevance and usability of the European Centre for Disease Prevention and Control (ECDC)'s 2010 HIV testing guidance.
Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin 2017, 22,

Haddad E, Lescure FX, Ghodhbane W, Lepage L, D'humieres C, Vindrios W, Yazdanpanah Y, Nataf P, Kirsch M
Left ventricular assist pump pocket infection: conservative treatment strategy for destination therapy candidates.
The International Journal of Artificial Organs 2017, 40, 90-95.

Delory T, Ferrand H, Grall N, Casalino E, Lafarge M, Melot B, Hajage D, Charpentier C, Aubier M, Tubach F, Bouvet E, Gault N, Yazdanpanah Y
Score for pulmonary tuberculosis in patients with clinical presumption of tuberculosis in a low-prevalence area.
Int J Tuberc Lung Dis 2017, 21, 1272-1279.

2016

Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin JS, Yazdanpanah Y
Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs.
Hepatology (Baltimore, Md.) 2016, 63, 1090-1101.

Delory T, Papot E, Rioux C, Charpentier C, Auge-Courtoi C, Michard F, Peytavin G, Descamps D, Matheron S, Yazdanpanah Y
Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.
Journal of Medical Virology 2016, 88, 1204-1210.

Picone O, Vauloup-Fellous C, D'Ortenzio E, Huissoud C, Carles G, Benachi A, Faye A, Luton D, Paty MC, Ayoubi JM, Yazdanpanah Y, Mandelbrot L, Matheron S
[Zika virus infection during pregnancy].
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction 2016, 45, 415-423.

Desnoyer A, Pospai D, Lê MP, Gervais A, Heurgué-Berlot A, Laradi A, Harent S, Pinto A, Salmon D, Hillaire S, Fontaine H, Zucman D, Simonpoli AM, Muret P, Larrouy L, Bernard Chabert B, Descamps D, Yazdanpanah Y, Peytavin G
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.
Journal of Hepatology 2016, 65, 40-47.

Yazdanpanah Y, Schwarzinger M
Generic antiretroviral drugs and HIV care: An economic review.
Medecine Et Maladies Infectieuses 2016, 46, 67-71.

Collarino R, Vergeylen U, Emeraud C, Latournèrie G, Grall N, Mammeri H, Messika-Zeitoun D, Vallois D, Yazdanpanah Y, Lescure FX, Bleibtreu A
Mitral endocarditis due to Rothia aeria with cerebral haemorrhage and femoral mycotic aneurysms, first French description.
New Microbes and New Infections 2016, 13, 40-42.

Delfraissy JF, Yazdanpanah Y, Levy Y
REACTing: the French response to infectious disease crises.
Lancet (London, England) 2016, 387, 2183-2185.

Lachâtre M, Rioux C, Dû DL, Fréchet-Jachym M, Veziris N, Bouvet E, Yazdanpanah Y
Bedaquiline plus delamanid for XDR tuberculosis.
The Lancet. Infectious Diseases 2016, 16, 294.

Pelat C, Kardaś-Słoma L, Birgand G, Ruppé E, Schwarzinger M, Andremont A, Lucet JC, Yazdanpanah Y
Hand Hygiene, Cohorting, or Antibiotic Restriction to Control Outbreaks of Multidrug-Resistant Enterobacteriaceae.
Infection Control and Hospital Epidemiology 2016, 37, 272-280.

Cuzin L, Dellamonica P, Yazdanpanah Y, Bouchez S, Rey D, Hoen B, Cabié A, DSG
Characteristics and consequences of medical care interruptions in HIV-infected patients in France.
Epidemiology and Infection 2016, 144, 2363-2370.

D'Ortenzio E, Matheron S, Yazdanpanah Y, de Lamballerie X, Hubert B, Piorkowski G, Maquart M, Descamps D, Damond F, Leparc-Goffart I
Evidence of Sexual Transmission of Zika Virus.
The New England Journal of Medicine 2016, 374, 2195-2198.

Préau M, Lorente N, Sagaon-Teyssier L, Champenois K, Gall JML, Mabire X, Spire B, Mora M, Yazdanpanah Y, Suzan M, ADgaACG
Factors associated with satisfaction with community-based non-medicalized counseling and testing using HIV rapid tests among MSM in France.
AIDS care 2016, 28, 1240-1248.

Matheron S, d'Ortenzio E, Leparc-Goffart I, Hubert B, de Lamballerie X, Yazdanpanah Y
Long-Lasting Persistence of Zika Virus in Semen.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2016, 63, 1264.

Bocket L, Peytavin G, Alidjinou EK, Ajana F, Choisy P, Lê M, Charpentier C, Descamps D, Yazdanpanah Y, Katlama C, Simon A, Calvez V, Marcelin AG, Soulie C
Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.
The Journal of Antimicrobial Chemotherapy 2016, 71, 2651-2653.

Sokal A, D'Ortenzio E, Houhou-Fidouh N, Brichler S, Dorchies J, Cabras O, Leparc-Goffart I, Yazdanpanah Y, Matheron S
Zika virus infection: report of the first imported cases in a Paris travel centre.
Journal of Travel Medicine 2016, 24,

Deuffic-Burban S, Obach D, Canva V, Pol S, Roudot-Thoraval F, Dhumeaux D, Mathurin P, Yazdanpanah Y
Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
Journal of Viral Hepatitis 2016, 23, 767-779.

Bottero J, Brouard C, Roudot-Thoraval F, Deuffic-Burban S, Hofliger P, Abergel A, Volant J, Dhumeaux D, Yazdanpanah Y, VHTEg
2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV.
Liver International: Official Journal of the International Association for the Study of the Liver 2016, 36, 1442-1449.

Birgand G, Leroy C, Nerome S, Luong Nguyen LB, Lolom I, Armand-Lefevre L, Ciotti C, Lecorre B, Marcade G, Fihman V, Nicolas-Chanoine MH, Pelat C, Perozziello A, Fantin B, Yazdanpanah Y, Ricard JD, Lucet JC
Costs associated with implementation of a strict policy for controlling spread of highly resistant microorganisms in France.
BMJ open 2016, 6, e009029.

Guglielmetti L, Le Dû D, Veziris N, Caumes E, Marigot-Outtandy D, Yazdanpanah Y, Robert J, Fréchet-Jachym M, MTMGotFNRCfMatPotFMTC
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?.
The European Respiratory Journal 2016, 48, 582-585.

Voiriot G, Visseaux B, Cohen J, Nguyen LB, Neuville M, Morbieu C, Burdet C, Radjou A, Lescure FX, Smonig R, Armand-Lefevre L, Mourvillier B, Yazdanpanah Y, Soubirou JF, Ruckly S, Houhou-Fidouh N, Timsit JF
Viral-bacterial coinfection affects the presentation and alters the prognosis of severe community-acquired pneumonia.
Crit Care 2016, 20, 375.

Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Souley Harouna n, Kighoma PM, Koundouno FR, Réné Lolamou n, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Gasasira Uwamahoro M, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Dortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, Barte de Sainte Fare E, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Allaford Duverger T, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D, JSG
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.
PLoS medicine 2016, 13, e1001967.

Loubet P, Palich R, Kojan R, Peyrouset O, Danel C, Nicholas S, Conde M, Porten K, Augier A, Yazdanpanah Y
Development of a Prediction Model for Ebola Virus Disease: A Retrospective Study in Nzérékoré Ebola Treatment Center, Guinea.
The American Journal of Tropical Medicine and Hygiene 2016, 95, 1362-1367.

2015

Obach D, Yazdanpanah Y, Esmat G, Avihingsanon A, Dewedar S, Durier N, Attia A, Anwar WA, Cousien A, Tangkijvanich P, Eholié SP, Doss W, Mostafa A, Fontanet A, Mohamed MK, Deuffic-Burban S
How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries.
Hepatology (Baltimore, Md.) 2015, 62, 31-39.

Yazdanpanah Y, Arribas JR, Malvy D
Treatment of Ebola virus disease.
Intensive Care Medicine 2015, 41, 115-117.

Parienti JJ, Lucet JC, Lefort A, Armand-Lefèvre L, Wolff M, Caron F, Cattoir V, Yazdanpanah Y
Empirical therapies among adults hospitalized for community-acquired upper urinary tract infections: A decision-tree analysis of mortality, costs, and resistance.
American Journal of Infection Control 2015, 43, e53-e59.

Mabileau G, Schwarzinger M, Flores J, Patrat C, Luton D, Epelboin S, Mandelbrot L, Matheron S, Yazdanpanah Y
HIV-serodiscordant couples desiring a child: 'treatment as prevention,' preexposure prophylaxis, or medically assisted procreation?.
American Journal of Obstetrics and Gynecology 2015, 213, 341.e1-12.

Caseris M, Burdet C, Lepeule R, Houhou N, Yeni P, Yazdanpanah Y, Joly V
[An update on measles].
La Revue De Medecine Interne 2015, 36, 339-345.

Ribadeau Dumas F, N’Diaye DS, Paireau J, Gautret P, Bourhy H, Le Pen C, Yazdanpanah Y
Cost-effectiveness of rabies post-exposure prophylaxis in the context of very low rabies risk: A decision-tree model based on the experience of France.
Vaccine 2015, 33, 2367-2378.

Yazdanpanah Y, Horby P, van Griensven J, Mentre F, Nguyen VK, Malvy JMD, Dunning J, Sissoko D, Delfraissy JF, Levy Y
Drug assessment in the Ebola virus disease epidemic in west Africa.
The Lancet. Infectious Diseases 2015, 15, 1258.

Horby PW, Endzt H, Muyembe-Tamfum JJ, van Griensven J, Gevao S, Goossens H, Malvy JMD, Haba NY, Yazdanpanah Y, Olliaro P, Semple C, de Jong M, Delamou A, Lang T, Carson G, Kennedy S
Ebola: Europe-Africa research collaborations.
The Lancet. Infectious Diseases 2015, 15, 1258-1259.

Soulie C, Peytavin G, Charpentier C, Lambert-Niclot S, Sayon S, Visseaux B, Simon A, Katlama C, Yazdanpanah Y, Descamps D, Calvez V, Marcelin AG
Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.
AIDS research and human retroviruses 2015, 31, 475-478.

Fofana DB, Charpentier C, Maïga AI, Lambert-Niclot S, Sayon S, Désiré N, Simon A, Yazdanpanah Y, Katlama C, Descamps D, Calvez V, Marcelin AG, Soulié C
Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.
The Journal of Antimicrobial Chemotherapy 2015, 70, 130-135.

Loubet P, Charpentier C, Visseaux B, Borbor A, Nuta C, Adu E, Chapplain JM, Baysah M, Tattevin P, Yazdanpanah Y, Descamps D
Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.
The Journal of Antimicrobial Chemotherapy 2015, 70, 1881-1884.

Charpentier C, Lee GQ, Rodriguez C, Visseaux B, Storto A, Fagard C, Molina JM, Katlama C, Yazdanpanah Y, Harrigan PR, Descamps D
Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
The Journal of Antimicrobial Chemotherapy 2015, 70, 2090-2096.

Raffi F, Yazdanpanah Y, Fagnani F, Laurendeau C, Lafuma A, Gourmelen J
Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database.
The Journal of Antimicrobial Chemotherapy 2015, 70, 2121-2128.

Ferrand H, Blanc-Gruyelle AL, Amsilli M, Lemaire X, Papot E, Papy E, Bervar J, Senneville E, Bouvet E, Yazdanpanah Y
Use of fluoroquinolones for the treatment of TB: 8 years of experience.
The Journal of Antimicrobial Chemotherapy 2015, 70, 3166-3167.

Belkacem A, Caseris M, Yazdanpanah Y
A Case of Aggregatibacter aphrophilus Multiple Abscess.
Open Forum Infectious Diseases 2015, 2, ofv031.

Feeney ER, Chung RT, Yazdanpanah Y
Current guidelines and prioritizing treatment of hepatitis C virus in HIV-infected patients.
Current opinion in HIV and AIDS 2015, 10, 323-329.

Loubet P, Mabileau G, Baysah M, Nuta C, Taylor M, Jusu H, Weeks H, Ingels A, Perennec-Olivier M, Chapplain JM, Cartier N, Mendiharat P, Raguin G, Tattevin P, Yazdanpanah Y
Likely effect of the 2014 Ebola epidemic on HIV care in Liberia.
AIDS (London, England) 2015, 29, 2347-2351.

Deconinck L, Yazdanpanah Y, Gilson RJ, Melliez H, Viget N, Joly V, Sabin CA
Time to initiation of antiretroviral therapy in HIV-infected patients diagnosed with an opportunistic disease: a cohort study.
HIV medicine 2015, 16, 219-229.

Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin JS, Yazdanpanah Y
Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review.
Journal of Viral Hepatitis 2015, 22, 213-229.

Deuffic-Burban S, Yazdanpanah Y
Fair prices for new direct-acting antiviral agents (DAAs) to make treatment for all affordable.
Gut 2015, 64, 1190-1191.

Pahlavan G, Burdet C, Laouénan C, Guiroy F, Bouscarat F, Tosini W, Yazdanpanah Y, Bouvet E
Predictors of return rate for an HIV-positive result in a French Voluntary Counseling and Testing centre.
International journal of STD & AIDS 2015, 26, 33-36.

Béraud G, Kazmercziak S, Beutels P, Levy-Bruhl D, Lenne X, Mielcarek N, Yazdanpanah Y, Boëlle PY, Hens N, Dervaux B
The French Connection: The First Large Population-Based Contact Survey in France Relevant for the Spread of Infectious Diseases.
PloS One 2015, 10, e0133203.

Charpentier C, Lê MP, Joly V, Visseaux B, Lariven S, Phung B, Yéni P, Yazdanpanah Y, Descamps D, Peytavin G, Landman R
Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up.
PloS One 2015, 10, e0134430.

Dubert M, Pourbaix A, Alkhoder S, Mabileau G, Lescure FX, Ghodhbane W, Belorgey S, Rioux C, Armand-Lefèvre L, Wolff M, Raffoul R, Nataf P, Yazdanpanah Y, Lucet JC
Sternal Wound Infection after Cardiac Surgery: Management and Outcome.
PloS One 2015, 10, e0139122.

Raben D, Mocroft A, Rayment M, Mitsura VM, Hadziosmanovic V, Sthoeger ZM, Palfreeman A, Morris S, Kutsyna G, Vassilenko A, Minton J, Necsoi C, Estrada VP, Grzeszczuk A, Johansson VS, Begovac J, Ong ELC, Cabié A, Ajana F, Celesia BM, Maltez F, Kitchen M, Comi L, Dragsted UB, Clumeck N, Gatell J, Gazzard B, d'Arminio Monforte A, Rockstroh J, Yazdanpanah Y, Champenois K, Jakobsen ML, Sullivan A, Lundgren JD, HASG
Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study.
PloS One 2015, 10, e0140845.

Potard V, Reynes J, Ferry T, Aubin C, Finkielsztejn L, Yazdanpanah Y, Costagliola D, FAC
Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice.
PloS One 2015, 10, e0144746.

Pommier JD, Ben Lasfar N, Van Grunderbeeck N, Burdet C, Laouénan C, Rioux C, Pierre-Audigier C, Meybeck A, Choudat L, Benchikh A, Nguyen S, Bouvet E, Yeni P, Yazdanpanah Y, Joly V
Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients.
Infectious Diseases (London, England) 2015, 47, 725-731.

Loubet P, Lescure FX, Lepage L, Kirsch M, Armand-Lefevre L, Bouadma L, Lariven S, Duval X, Yazdanpanah Y, Joly V
Endocarditis due to gram-negative bacilli at a French teaching hospital over a 6-year period: clinical characteristics and outcome.
Infectious Diseases (London, England) 2015, 47, 889-895.

Freedberg KA, Possas C, Deeks S, Ross AL, Rosettie KL, Di Mascio M, Collins C, Walensky RP, Yazdanpanah Y
The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis.
Journal of Virus Eradication 2015, 1, 245-249.

2014

Mourad A, Deuffic-Burban S, Ganne-Carrié N, Renaut-Vantroys T, Rosa I, Bouvier AM, Launoy G, Cattan S, Louvet A, Dharancy S, Trinchet JC, Yazdanpanah Y, Mathurin P
Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: A modeling approach.
Hepatology (Baltimore, Md.) 2014, 59, 1471-1481.

Rahier J, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees C, MacMahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel J
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
Journal of Crohn's and Colitis 2014, 8, 443-468.

Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux GP, Canva V, Deltenre P, Roudot-Thoraval F, Larrey D, Dhumeaux D, Mathurin P, Yazdanpanah Y
Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Journal of Hepatology 2014, 61, 7-14.

Krastinova E, Bani-Sadr F, Fromentin D, Goujard C, Hessamfar M, Yazdanpanah Y, Pol S, Cacoub P, Perronne C, Carrat F
Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral response.
The Journal of Infection 2014, 68, 462-466.

Neulier C, Birgand G, Ruppé E, Armand-Lefèvre L, Lolom I, Yazdanpanah Y, Lucet JC, Andremont A
Enterobacteriaceae bacteremia: Risk factors for ESBLPE.
Médecine et maladies infectieuses 2014, 44, 32-38.

Matheron S, Baize S, Lerat I, Houhou N, Yazdanpanah Y
Ebola: should we consider influenza vaccination?.
Lancet (London, England) 2014, 384, 2023-2024.

Birgand G, Schwarzinger M, Perozziello A, Lolom I, Pelat C, Armand-Lefevre L, Buzzi JC, Andremont A, Yazdanpanah Y, Lucet JC
Prolonged hospital stay, an adverse effect of strict national policy for controlling the spread of highly resistant microorganisms.
Infection Control and Hospital Epidemiology 2014, 35, 1427-1429.

Loubet P, Charpentier C, Visseaux B, Nuta C, Adu E, Chapplain JM, Baysah M, Walters-Doe S, Tattevin P, Peytavin G, Yazdanpanah Y, Descamps D
Short communication: Prevalence of HIV-1 transmitted drug resistance in Liberia.
AIDS research and human retroviruses 2014, 30, 863-866.

Obach D, Deuffic-Burban S, Esmat G, Anwar WA, Dewedar S, Canva V, Cousien A, Doss W, Mostafa A, Pol S, Buti M, Siebert U, Fontanet A, Mohamed MK, Yazdanpanah Y
Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2014, 58, 1064-1071.

Burdet C, Lepeule R, Duval X, Caseris M, Rioux C, Lucet JC, Yazdanpanah Y
Quinolones versus macrolides in the treatment of legionellosis: a systematic review and meta-analysis.
The Journal of Antimicrobial Chemotherapy 2014, 69, 2354-2360.

Charpentier C, Choquet M, Joly V, Yeni P, Visseaux B, Caseris M, Brun-Vézinet F, Yazdanpanah Y, Peytavin G, Descamps D, Landman R
Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.
The Journal of Antimicrobial Chemotherapy 2014, 69, 2819-2825.

Yazdanpanah Y, Champenois K
Assessing characteristics of hidden epidemics to design the most efficient HIV testing strategies.
AIDS (London, England) 2014, 28, 1831-1833.

Nguyen LBL, Harent S, Peytavin G, Visseaux B, Bastard JP, Dubourg O, Lariven S, Patrick Yeni n, Yazdanpanah Y, Lescure FX
Skeletal muscle toxicity associated with emtricitabine/rilpivirine/tenofovir fixed-dose combination: a case report.
AIDS (London, England) 2014, 28, 1995-1997.

Ouattara EN, Ross EL, Yazdanpanah Y, Wong AY, Robine M, Losina E, Moh R, Walensky RP, Danel C, Paltiel AD, Eholié SP, Freedberg KA, Anglaret X
Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire.
Journal of Acquired Immune Deficiency Syndromes (1999) 2014, 66, 294-302.

Caseris M, Houhou N, Longuet P, Rioux C, Lepeule R, Choquet C, Yazdanpanah Y, Yeni P, Joly V
French 2010-2011 measles outbreak in adults: report from a Parisian teaching hospital.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2014, 20, O242-244.

Birgand G, Armand-Lefevre L, Lepainteur M, Lolom I, Neulier C, Reibel F, Yazdanpanah Y, Andremont A, Lucet JC
Introduction of highly resistant bacteria into a hospital via patients repatriated or recently hospitalized in a foreign country.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases [RESEARCH NOTE] 2014, 20, O887-890.

Almudimeegh A, Rioux C, Ferrand H, Crickx B, Yazdanpanah Y, Descamps V
Drug reaction with eosinophilia and systemic symptoms, or virus reactivation with eosinophilia and systemic symptoms as a manifestation of immune reconstitution inflammatory syndrome in a patient with HIV?.
The British Journal of Dermatology [CASE REPORT] 2014, 171, 895-898.

Cousien A, Obach D, Deuffic-Burban S, Mostafa A, Esmat G, Canva V, El Kassas M, El-Sayed M, Anwar WA, Fontanet A, Mohamed MK, Yazdanpanah Y
Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt.
BMC medical research methodology 2014, 14, 39.

N'Diaye DS, Schwarzinger M, Obach D, Poissy J, Matheron S, Casalino E, Yazdanpanah Y
Effectiveness and cost of quick diagnostic tests to determine tetanus immunity in patients with a wound in French emergency departments.
BMC infectious diseases 2014, 14, 603.

Ferraretto X, Estellat C, Damond F, Longuet P, Epelboin S, Demailly P, Yazbeck C, Llabador MA, Pasquet B, Yazdanpanah Y, Matheron S, Patrat C
Timing of intermittent seminal HIV-1 RNA shedding in patients with undetectable plasma viral load under combination antiretroviral therapy.
PloS One 2014, 9, e88922.

N'Diaye DS, Yazdanpanah Y, Krivine A, Andrieu T, Rozenberg F, Picone O, Tsatsaris V, Goffinet F, Launay O
Predictive factors of cytomegalovirus seropositivity among pregnant women in Paris, France.
PloS One 2014, 9, e89857.

Casalino E, Choquet C, Leleu A, Hellmann R, Wargon M, Juillien G, Yazdanpanah Y, Bouvet E
Trends in Condom Use and Risk Behaviours after Sexual Exposure to HIV: A Seven-Year Observational Study.
PloS One 2014, 9, e104350.

Poletto C, Pelat C, Levy-Bruhl D, Yazdanpanah Y, Boelle P, Colizza V
Assessment of the Middle East respiratory syndrome coronavirus (MERS-CoV) epidemic in the Middle East and risk of international spread using a novel maximum likelihood analysis approach.
Euro Surveillance: Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin 2014, 19,

2013

Deuffic-Burban S, Yazdanpanah Y
Mathematical modeling: a tool for selecting agents with complementary modes of action?.
Journal of Hepatology 2013, 59, 1346-1348.

Vaznaisiene D, Beltrand E, Laiskonis AP, Yazdanpanah Y, Migaud H, Senneville E
Major amputation of lower extremity: prognostic value of positive bone biopsy cultures.
Orthopaedics & traumatology, surgery & research: OTSR 2013, 99, 88-93.

Chaix ML, Seng R, Frange P, Tran L, Avettand-Fenoël V, Ghosn J, Reynes J, Yazdanpanah Y, Raffi F, Goujard C, Rouzioux C, Meyer L, APCSG
Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2013, 56, 880-887.

Cuzin L, Allavena C, Pugliese P, Rey D, Hoen B, Poizot-Martin I, Cabie A, Yazdanpanah Y, DSG
Can the "seek, test, treat, and retain" strategy be effective in France?.
Journal of Acquired Immune Deficiency Syndromes (1999) 2013, 62, e119-121.

Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P, SI
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
Journal of acquired immune deficiency syndromes (1999) 2013, 63, 77-85.

Cotte L, Dellamonica P, Raffi F, Yazdanpanah Y, Molina JM, Boué F, Urata Y, Chan HP, Zhu L, Chang I, Bertz R, Hanna GJ, Grasela DM, Hwang C
Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects.
Journal of Acquired Immune Deficiency Syndromes (1999) 2013, 63, 346-354.

Barau C, Furlan V, Yazdanpanah Y, Fagard C, Molina JM, Taburet AM, Barrail-Tran A
Characterization of binding of raltegravir to plasma proteins.
Antimicrobial Agents and Chemotherapy 2013, 57, 5147-5150.

Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, Colin de Verdiere N, Tabuteau S, Raffi F, Cabie A, Chene G, Yeni P, S1ATG
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Antimicrobial Agents and Chemotherapy 2013, 57, 758-765.

Champenois K, Cousien A, Ndiaye B, Soukouna Y, Baclet V, Alcaraz I, Choisy P, Chaud P, Velter A, Gallay A, Yazdanpanah Y
Risk factors for syphilis infection in men who have sex with men: results of a case-control study in Lille, France.
Sexually Transmitted Infections 2013, 89, 128-132.

Lorente N, Champenois K, Blanche J, Préau M, Suzan-Monti M, Mora M, Fugon L, Carrieri MP, Sagaon-Teyssier L, Le Gall JM, Spire B, Yazdanpanah Y
Investigating Recent Testing among MSM: Results from Community-Based HIV Rapid Testing Attendees in France.
Journal of Sexually Transmitted Diseases 2013, 2013, 648791.

Champenois K, Cousien A, Cuzin L, Le Vu S, Deuffic-Burban S, Lanoy E, Lacombe K, Patey O, Béchu P, Calvez M, Semaille C, Yazdanpanah Y
Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study.
BMC infectious diseases 2013, 13, 200.

Birgand G, Ruimy R, Schwarzinger M, Lolom I, Bendjelloul G, Houhou N, Armand-Lefevre L, Andremont A, Yazdanpanah Y, Lucet JC
Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs.
Antimicrobial Resistance and Infection Control 2013, 2, 30.

Charpentier C, Fagard C, Colin C, Katlama C, Molina JM, Jacomet C, Visseaux B, Taburet AM, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D, ATTsg
Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
PloS One 2013, 8, e53621.

Charpentier C, Champenois K, Gervais A, Landman R, Joly V, Le Gac S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, Yazdanpanah Y
Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients.
PloS One 2013, 8, e59205.

Bacchus C, Cheret A, Avettand-Fenoël V, Nembot G, Mélard A, Blanc C, Lascoux-Combe C, Slama L, Allegre T, Allavena C, Yazdanpanah Y, Duvivier C, Katlama C, Goujard C, Seksik BCP, Leplatois A, Molina JM, Meyer L, Autran B, Rouzioux C, OA1sg
A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection.
PloS One 2013, 8, e64219.

Yazdanpanah Y, Perelman J, DiLorenzo MA, Alves J, Barros H, Mateus C, Pereira J, Mansinho K, Robine M, Park JE, Ross EL, Losina E, Walensky RP, Noubary F, Freedberg KA, Paltiel AD
Routine HIV screening in Portugal: clinical impact and cost-effectiveness.
PloS One 2013, 8, e84173.

2012

Yazdanpanah Y, Walensky RP, Rozenbaum W, Yeni P, Paltiel AD
What is a modest public health impact?.
Archives of Internal Medicine 2012, 172, 521-522; author reply 522-523.

Deuffic-Burban S, Castel H, Wiegand J, Manns MP, Wedemeyer H, Mathurin P, Yazdanpanah Y
Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis.
Journal of Hepatology 2012, 57, 260-266.

Gros C, Yazdanpanah Y, Vachet A, Roussel-Delvallez M, Senneville E, Lemaire X
Skin and soft tissue infections due to Panton-Valentine leukocidin producing Staphylococcus aureus.
Medecine Et Maladies Infectieuses 2012, 42, 488-494.

Deuffic-Burban S, Yazdanpanah Y
It is time to change the paradigm for hepatitis C virus testing.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2012, 54, 1272-1274.

Charpentier C, Larrouy L, Visseaux B, Landman R, Levittas M, Storto A, Damond F, Yazdanpanah Y, Yeni P, Brun-Vézinet F, Descamps D
Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
The Journal of Antimicrobial Chemotherapy 2012, 67, 1459-1461.

Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, Ajana F, Melliez H, Paltiel AD, Freedberg KA, Yazdanpanah Y, CEoPAC(i
Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.
AIDS (London, England) 2012, 26, 45-56.

Pasquet A, Ajana F, Melliez H, Giurca C, Poissy J, Yazdanpanah Y
Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load.
AIDS (London, England) 2012, 26, 1726-1728.

Fagard C, Colin C, Charpentier C, Rami A, Jacomet C, Yeni P, Vittecoq D, Katlama C, Molina JM, Descamps D, Chêne G, Yazdanpanah Y, A1TTG
Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.
Journal of Acquired Immune Deficiency Syndromes (1999) 2012, 59, 489-493.

Henard S, Jeanmaire E, Nguyen Y, Yazdanpanah Y, Cheret A, Hoen B, Rey D, Borel A, Chavanet P, May T, Rabaud C, IG
Is total community viral load a robust predictive marker of the efficacy of the TasP strategy?.
Journal of Acquired Immune Deficiency Syndromes (1999) 2012, 61, 400-402.

Senneville E, Gaworowska D, Topolinski H, Devemy F, Nguyen S, Singer B, Beltrand E, Legout L, Caillaux M, Descamps D, Canonne JP, Yazdanpanah Y
Outcome of patients with diabetes with negative percutaneous bone biopsy performed for suspicion of osteomyelitis of the foot.
Diabet Med 2012, 29, 56-61.

Pichenot M, Deuffic-Burban S, Cuzin L, Yazdanpanah Y
Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials.
HIV Med 2012, 13, 148-55.

Legout L, Sarraz-Bournet B, D'Elia PV, Devos P, Pasquet A, Caillaux M, Wallet F, Yazdanpanah Y, Senneville E, Haulon S, Leroy O
Characteristics and prognosis in patients with prosthetic vascular graft infection: a prospective observational cohort study.
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2012, 18, 352-358.

Champenois K, Le Gall JM, Jacquemin C, Jean S, Martin C, Rios L, Benoit O, Vermoesen S, Lert F, Spire B, Yazdanpanah Y
ANRS-COM'TEST: description of a community-based HIV testing intervention in non-medical settings for men who have sex with men.
BMJ open 2012, 2, e000693.

Deuffic-Burban S, Mathurin P, Pol S, Larsen C, Roudot-Thoraval F, Desenclos JC, Dhumeaux D, Yazdanpanah Y
Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis.
Gut 2012, 61, 290-296.

Poissy J, Champenois K, Dewilde A, Melliez H, Georges H, Senneville E, Yazdanpanah Y
Impact of Herpes simplex virus load and red blood cells in cerebrospinal fluid upon herpes simplex meningo-encephalitis outcome.
BMC infectious diseases 2012, 12, 356.

Meybeck A, Lecomte L, Valette M, Van Grunderbeeck N, Boussekey N, Chiche A, Georges H, Yazdanpanah Y, Leroy O
Should highly active antiretroviral therapy be prescribed in critically ill HIV-infected patients during the ICU stay? A retrospective cohort study.
AIDS research and therapy 2012, 9, 27.

Colombie V, Pugliese-Wehrlen S, Deuffic-Burban S, Cuzin L, Pugliese P, Katlama C, Poizot-Martin I, Raffi F, Cabie A, Dellamonica P, Yazdanpanah Y, D
Mean cost of a first combination antiretroviral therapy in HIV-infected patients in France, and determinants of expensive drugs prescription.
International journal of STD & AIDS 2012, 23, 865-869.

Pellissier G, Yazdanpanah Y, Adehossi E, Tosini W, Madougou B, Ibrahima K, Lolom I, Legac S, Rouveix E, Champenois K, Rabaud C, Bouvet E
Is universal HBV vaccination of healthcare workers a relevant strategy in developing endemic countries? The case of a university hospital in Niger.
PloS one 2012, 7, e44442.

Hocqueloux L, Choisy P, Le Moal G, Borsa-Lebas F, Plainchamp D, Legac E, Prazuck T, de la Tribonnière X, Yazdanpanah Y, Parienti JJ
Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted study.
PloS One 2012, 7, e49289.

2009

Guiguet M, Kendjo E, Carcelain G, Abgrall S, Mary-Krause M, Tattevin P, Yazdanpanah Y, Costagliola D, Duval X, FACEG
CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells/mm3.
Antiviral Therapy 2009, 14, 451-457.